{"id":1004144,"date":"2026-09-17T07:32:05","date_gmt":"2026-09-17T11:32:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/"},"modified":"2026-09-17T07:32:05","modified_gmt":"2026-09-17T11:32:05","slug":"axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/","title":{"rendered":"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Sept.  17, 2026  (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer\u2019s disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana.<\/p>\n<p align=\"justify\">Details of the data presentations are as follows:<\/p>\n<p>\n        <strong><br \/>\n          <em>Alzheimer\u2019s Disease Agitation:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Agitation in Alzheimer\u2019s Disease: Association with Increased Clinical Burden, Healthcare Utilization, and Mortality Among Patients in Long-term Care<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Malcolm Fraser, MD, CMD, Medical Director, Red Rock Pharmacy, Salt Lake City, UT<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 139<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Real-World Treatment Patterns and Clinical Management of Alzheimer\u2019s Disease Agitation<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Amita Patel, MD, CMD, MHA, CPE, private practice, Dayton OH<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 145<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Results of a Survey of Care Partners of People Living with Alzheimer\u2019s Disease Agitation<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Brent P. Forester, MD, MSc; Professor, Department of Psychiatry, Tufts University School of Medicine, MA<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 146<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong><br \/>\n          <em>Major Depressive Disorder:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Anti-Anhedonic Effects of Dextromethorphan-Bupropion Mediate Improvements in Functioning and Quality of Life in Major Depressive Disorder<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Thursday, September 17, 9:00 &#8211; 10:00 a.m. at the \u201cLatest Discoveries &amp; Emerging Trends in MDD\u201d session, and 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Andrew Cutler, MD, Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University, NY<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 75<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Real-World Clinical Outcomes of Patients Switching to Treatment with Dextromethorphan-Bupropion (45 mg\/105 mg)<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Joel L. Young, MD, Medical Director of the Rochester Center for Behavioral Medicine, MI<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 129<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Anxiolytic Effects of Dextromethorphan-Bupropion (45mg\/105mg): Post Hoc Analyses Across Trials in Major Depressive Disorder<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 101<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Effects of Dextromethorphan-Bupropion (45mg\/105mg) in Participants with Major Depressive Disorder and Anxious Distress<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 102<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong><br \/>\n          <em>Excessive Daytime Sleepiness in Narcolepsy and OSA:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Solriamfetol for Excessive Daytime Sleepiness in Narcolepsy and OSA: Post-hoc Multi-dimensional Composite Endpoint Analysis of Phase 3 Trials<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Wermter, Ellen E., FNP-BC, DBSM, FAASM, Restorative Sleep Medicine, Charlottesville, VA<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 156<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong><br \/>\n          <em>Narcolepsy:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Cognitive and Functional Outcomes from\u00a0the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Trial of AXS-12 in Narcolepsy with Cataplexy<br \/><strong>Presentation Date and Time:\u00a0<\/strong>Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Bruce Corser MD, FAASM, Medical Director of Intrepid Research, Cincinnati, OH<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 154<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt\">\n          <strong>Title:<\/strong> Symptom Burden and Quality of Life in Patients with Narcolepsy Who Continue to Experience Cataplexy: Subgroup Analysis from the CRESCENDO Survey<br \/><strong>Presentation Date and Time: <\/strong>Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central Time<br \/><strong>Lead Author:<\/strong> Michael J. Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY<br \/><strong>Poster\u00a0<\/strong><strong>Number:<\/strong> 155<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>About Axsome Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer\u2019s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain\u2019s biggest problems so patients and their loved ones can flourish. For more information, please visit us at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Seqt7FpRCoITTfRMAWA024HhH5Q0wlIz1Mk8E_lkZ_Q8UkXoDwWkD8Usqwh95O402bCfRh5lJKhaqptPyfp98A==\" rel=\"nofollow\" target=\"_blank\">www.axsome.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N26_5DIT_J7qEAVgQL8RWnYz7pP_ogS00D7S68c0v7-MfWbVIqfu0cYB1S28kakJbD_JKu_M8wTRhr6a2Dy_ki9aAh8AM5hXp9cnDxVfGsY=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qlncvcwVgXp2OFglwNfTFRXibLLvMU98uOz8P7vMj4MWEnos9_Ex0hKcXzXGaJQx\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain matters discussed in this press release are \u201cforward-looking statements\u201d. The Company may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company\u2019s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company\u2019s SUNOSI<sup>\u00ae<\/sup>, AUVELITY<sup>\u00ae<\/sup>, and SYMBRAVO<sup>\u00ae<\/sup> products and the success of the Company\u2019s efforts to obtain any additional indication(s) with respect to solriamfetol and\/or AXS-05; the Company\u2019s ability to maintain and expand payer coverage; the success, timing and cost of the Company\u2019s ongoing clinical trials and anticipated clinical trials for the Company\u2019s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company\u2019s ability to fully fund the Company\u2019s disclosed clinical trials, which assumes no material changes to the Company\u2019s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company\u2019s ongoing clinical trials, and\/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (\u201cNDA\u201d) for any of the Company\u2019s current product candidates; the Company\u2019s ability to fund additional clinical trials to continue the advancement of the Company\u2019s product candidates; the timing of and the Company\u2019s ability to obtain and maintain U.S. Food and Drug Administration (\u201cFDA\u201d) or other regulatory authority approval of, or other action with respect to, the Company\u2019s product candidates, including statements regarding the timing of any NDA submission; the Company\u2019s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company\u2019s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company\u2019s research and development programs and collaborations; the success of the Company\u2019s license agreements; the acceptance by the market of the Company\u2019s products and product candidates, if approved; the Company\u2019s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company\u2019s commercial launch of its other product candidates, if approved, and the potential impact on the Company\u2019s anticipated cash runway; the Company\u2019s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company\u2019s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.<\/p>\n<p align=\"justify\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Ashley Dong<br \/>Senior Director, Investor Relations<br \/>(929) 687-1614<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sR-O1lvtlALL5L8GvxMR-TW062M51AsRn4thW5nRhb961jhmCTYjoLEurqyMH9fQsgxYt9XabQIcfh6x5AhXWeOuvFahXkqjVBG8LRzUZSY=\" rel=\"nofollow\" target=\"_blank\">adong@axsome.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media:<\/strong><br \/>\n        <br \/>Darren Opland<br \/>Senior Director, Corporate Communications<br \/>(929) 837-1065<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jOuw7-e3cswEMOfO3j4qP2ikY9aUyVv5B-B0OneGaiEY_EGoSwc0zY364Yrso-YDnK-SExWpNp10YSdyBEzuTGnmCFcqgr0Qe-PvnzIGMvU=\" rel=\"nofollow\" target=\"_blank\">dopland@axsome.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDE1YThmZDAtZDJhZi00ZWZmLThmZjgtNTkwNWY2YWJhNmU5LTEwMzAxMzAtMjAyNi0wOS0xNy1lbg==\/tiny\/Axsome-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer\u2019s disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana. Details of the data presentations are as follows: Alzheimer\u2019s Disease Agitation: Title: Agitation in Alzheimer\u2019s Disease: Association with Increased Clinical Burden, Healthcare Utilization, and Mortality Among Patients in Long-term CarePresentation Date and Time:\u00a0Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central TimeLead Author: Malcolm Fraser, MD, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1004144","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer\u2019s disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana. Details of the data presentations are as follows: Alzheimer\u2019s Disease Agitation: Title: Agitation in Alzheimer\u2019s Disease: Association with Increased Clinical Burden, Healthcare Utilization, and Mortality Among Patients in Long-term CarePresentation Date and Time:\u00a0Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central TimeLead Author: Malcolm Fraser, MD, &hellip; Continue reading &quot;Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-17T11:32:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026\",\"datePublished\":\"2026-09-17T11:32:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/\"},\"wordCount\":1368,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/\",\"name\":\"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=\",\"datePublished\":\"2026-09-17T11:32:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/","og_locale":"en_US","og_type":"article","og_title":"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - Market Newsdesk","og_description":"NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) &#8212; Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer\u2019s disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana. Details of the data presentations are as follows: Alzheimer\u2019s Disease Agitation: Title: Agitation in Alzheimer\u2019s Disease: Association with Increased Clinical Burden, Healthcare Utilization, and Mortality Among Patients in Long-term CarePresentation Date and Time:\u00a0Thursday, September 17, 12:00 &#8211; 3:30 p.m., and Friday, September 18, 12:00 &#8211; 3:30 p.m. Central TimeLead Author: Malcolm Fraser, MD, &hellip; Continue reading \"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-17T11:32:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026","datePublished":"2026-09-17T11:32:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/"},"wordCount":1368,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/","name":"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=","datePublished":"2026-09-17T11:32:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODY2NCM3ODM4NjUxIzIwMTg1NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-presents-ten-posters-exemplifying-its-innovative-psychiatry-and-neurology-portfolio-at-psych-congress-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1004144"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004144\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1004144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1004144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1004144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}